Patents Assigned to Merck
  • Process for purifying human papillomavirus virus-like particles
    Patent number: 6602697
    Abstract: A process for purifying papillomavirus virus-like particles (VLPs) includes the step of passing a partially purified VLP-containing solution through a hydroxyapatite chromatography column. The VLPs are then eluted using a buffer containing phosphate anion. The advantages of this method include the recovery of a high yield of intact VLPs.
    Type: Grant
    Filed: May 1, 2001
    Date of Patent: August 5, 2003
    Assignee: Merck & Co., Inc.
    Inventor: James C. Cook, III
  • Polyesters containing (meth)acrylate end groups
    Patent number: 6602963
    Abstract: The invention describes polyesters containing (meth)acrylate end groups, of the general formula (I) CH2═CRCOO—PE—OCOCR═CH2 where R=CH3 or H, where PE=[—A—OCO—B—COO—]m—A—, [—CHR′—COO—]n—A—[—OCOCHR′—]n, or combinations thereof, in which A is an alkylidene radical having 2-20 carbon atoms or an alkoxylidene radical having 2-1000, preferably 2-500, alkoxylidene units, B is a saturated alkylidene radical having 2-10 carbon atoms, R′ is H or CH3, m is 1-100, n is 1-100, and, if both m and n are present, the sum m+n is 2-200, where the polyesters containing (meth)acrylate end groups are characterized in that a) the content of short-chain di(meth)acrylates (II) CH2═CRCOO—A—OCOCR═CH2 is <5% by weight, b) the content of hydroxyl groups is <0.25 mol/mol of (meth)acrylate, and c) the APHA color number is <200.
    Type: Grant
    Filed: January 14, 2002
    Date of Patent: August 5, 2003
    Assignee: Merck Patent GmbH
    Inventors: Werner Siol, Peter Pokinskyj
  • Heterogeneously catalyzed process for cross coupling alkenyl halides with boronic acids
    Patent number: 6603013
    Abstract: The present invention relates to a process wherein heterogeneous finely-dispersed palladium catalysts are used in a cross-coupling reaction of alkenyl halides and aryl or heteroaryl boronic acids in the presence of base in an aprotic solvent to produce aryl- or heteroaryl-olefin compounds of Formula I:
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: August 5, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Yongkui Sun, Carl LeBlond, John R. Sowa, Jr.
  • Adhesion receptor antagonists
    Patent number: 6602876
    Abstract: Compounds of the formula I wherein R1, R2 and R3 have the meanings defined herein, and also their physiologically acceptable salts, inhibit the binding of fibrinogen to the corresponding receptor and can be employed for the treatment of thromboses, osteoporoses, oncoses, apoplexy, cardiac infarct, ischaemias, inflammations, arteriosclerosis and osteolytic disorders.
    Type: Grant
    Filed: November 2, 1995
    Date of Patent: August 5, 2003
    Assignee: Merck Patent GmbH
    Inventors: Joachim Gante, Horst Juraszyk, Peter Raddatz, Hanns Wurziger, Sabine Bernotat-Danielowski, Guido Melzer, Matthias Wiesner, Claus Fittschen
  • Transparent medium with angular-selective transmitting or reflecting properties
    Patent number: 6602340
    Abstract: The invention relates to a transparent medium comprising pearl lustre pigments having angle-selective reflection and/or transmission properties and to the use thereof, especially in transparent thermal insulation systems (TIMs).
    Type: Grant
    Filed: June 19, 2000
    Date of Patent: August 5, 2003
    Assignee: Merck Patent GmbH
    Inventors: Christina Schank, Gerhard Pfaff, Alexandra Brownfield, Joachim Weitzel, Wolfgang Hechler
  • Apparatus and method for processing phone-in prescriptions
    Publication number: 20030144876
    Abstract: An apparatus and method are disclosed for processing phone-in prescription requests. The apparatus is in the form of a prescription processing network that includes a prescription processing system and a communication device remotely located from the prescription processing system. The communication device is used to establish a communication channel with the prescription processing system and submit a prescription request over the communication channel. A pharmacist, associated with the prescription processing system, prepares a completed prescription form based, at least in part, on the submitted prescription request. The prescription processing network also includes a pharmacy for receiving the completed prescription form, and filling the prescription request based on the completed prescription form.
    Type: Application
    Filed: January 28, 2002
    Publication date: July 31, 2003
    Applicant: Merck-Medco Managed Care, LLC
    Inventors: Diana L. Kosinski, Mark W. Sullivan, Steven M. McNamara, Melissa Russo
  • Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
    Publication number: 20030144327
    Abstract: Polymorphic, amorphous and hydrated forms of the title compound having the following structure: 1
    Type: Application
    Filed: January 14, 2003
    Publication date: July 31, 2003
    Applicant: Merck & Co., Inc.
    Inventor: Louis S. Crocker
  • Method of establishing synthesis paths
    Patent number: 6600970
    Abstract: A method of establishing a synthesis path in a multiplicity of potentially interlinakable reactions, and a computer program to prepare a synthesis path.
    Type: Grant
    Filed: September 5, 2001
    Date of Patent: July 29, 2003
    Assignee: Merck Patent GmbH
    Inventor: Klemens Bley
  • Process for preparing 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfony)phenyl]ethanone
    Patent number: 6600046
    Abstract: The process for preparing 1-(6-methylpyridin-3-yl)-2-[(4-methlsulfonyl)-phenyl]ethanone of the formula I: In a first step, 4-(methylthio)phenylacetonitrile is condensed with a 6-methylnicotinic ester to give 3-[2-(4-(methlthio)phenyl)-2-cyanoacetyl](6-methyl)pyridine of the formula II: In a second step, the compound of formula II is hydrolyzed and decarboxylated under acidic conditions using a mixture of acetic acid and a mineral acid, to give 3-[2-(4-(methylthio)phenyl)acetyl](6-methyl)pyridine of the formula III: Finally, in a last step, the compound of formula III is oxidized to give the end product.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: July 29, 2003
    Assignees: Merck & Co., Inc., Lonza AG
    Inventors: Yves Bessard, James Edward Leresche
  • Process for the synthesis of (2R, 2-alpha-R, 3A)-2-[1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-1, 4-oxazine
    Patent number: 6600040
    Abstract: The present invention is concerned with novel processes for the preparation of (2R, 2-alpha-R, 3a)-2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-1,4-oxazine. This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: July 29, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Karel M. Jos Brands, Fuh-Rong Tsay, Karen M. Conrad, Matthew M. Zhao
  • Film
    Patent number: 6599443
    Abstract: The invention relates to an optical retardation film comprising a layer of an anisotropic polymer material with an optical axis substantially parallel to the plane of the layer. The invention furthermore relates to a process of preparing the optical retardation film, to the use of such an optical retardation film in liquid crystal displays, and to a liquid crystal display device comprising a liquid crystal cell and such an optical retardation film.
    Type: Grant
    Filed: August 31, 2000
    Date of Patent: July 29, 2003
    Assignees: Rockwell Technologies, LLC, Merck Patent GmbH
    Inventors: Nicholas Sharples, Gabrielle Egan, Young Chung, Zhiming Zhuang, Zili Li, Bruce K. Winker, Jane H. Hanamoto, David Coates
  • Interference pigments with great color strength
    Patent number: 6599355
    Abstract: The invention relates to interference pigments with a great color strength that are based on multicoated platelet-shaped substrates that have at least one series of layers from (A) a highly refractive coating that consists of a mixture of TiO2 and Fe2O3 in ratio of 1:0.1 to 1:5 and optionally one or more metal oxides in amounts of ≦20% by weight based on layer (A), (B) a colorless coating with a refractive index n≦1.8, (C) a colorless coating with a refractive index of n 1.8, (D) an absorptive coating with a refractive index of n 1.8, and optionally (E) an outer protective layer.
    Type: Grant
    Filed: April 26, 2002
    Date of Patent: July 29, 2003
    Assignee: Merck Patent GmbH
    Inventors: Christoph Schmidt, Klaus Bernhardt, Sabine Schoen, Dieter Heinz
  • Growth hormone secretagogue related receptors and nucleic acids
    Patent number: 6599718
    Abstract: This invention relates to a new family of receptors, growth hormone secretagogue-related receptors, which exhibit moderate sequence identity to both the growth hormone secretagogue receptor (GHS-R) and the neurotensin receptor (NT-R). These newly identified receptors are expressed in a diverse set of tissues. This invention also relates to nucleic acids encoding these receptors, and to the use of these receptors to identify ligands that modulate growth hormone release as well as other modulators of endocrine function.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: July 29, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Qingyun Liu, Andrew D. Howard, Karen Kulju McKee
  • Nematic liquid-crystal composition
    Publication number: 20030136945
    Abstract: The invention relates to nematic liquid-crystal compositions comprising bisalkenyl compounds of the formula I 1
    Type: Application
    Filed: October 15, 2002
    Publication date: July 24, 2003
    Applicant: Merck Paten GmbH
    Inventors: Harald Hirschmann, Sven Schupfer, Marcus Reuter
  • Human neuronal nicotinic acetylcholine receptor compositions and methods employing same
    Publication number: 20030138911
    Abstract: Nucleic acid molecules encoding human neuronal nicotinic acetylcholine receptor alpha and beta subunits, mammalian and amphibian cells containing the nucleic acid molecules, and methods for producing alpha and beta subunits are provided. In particular, nucleic acid molecules encoding &agr;6 subunits and molecules encoding &bgr;3 subunits of human neuronal nicotinic acetylcholine receptors are provided. In addition, combinations of a plurality of subunits, such as one or more of &agr;1, &agr;2, &agr;3, &agr;4, &agr;5, &agr;6 and/or &agr;7 subunits in combination with one or more of &bgr;3 subunits or such as one or more of &bgr;2, &bgr;3 and/or &bgr;4 subunits in combination with an &agr;6 subunit are provided.
    Type: Application
    Filed: January 23, 2003
    Publication date: July 24, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Kathryn J. Elliott, Michael M. Harpold
  • Method of purifying thiamine phosphates
    Patent number: 6596865
    Abstract: The invention relates to a method for removing phosphoric acid, thiamine triphosphate and higher thiamine phosphates from solutions that contain phosphoric acid, thiamine monophosphate, thiamine diphosphate, diamine triphosphate and higher phosphates. The inventive method is characterized by passing the phosphoric acid solution of thiamine phosphates over a non-ionogenic adsorber resin which comprises unsaturated cyclic nitrogen bases and eluting thiamine monophosphate and thiamine diphosphate with a suitable solvent.
    Type: Grant
    Filed: June 11, 2001
    Date of Patent: July 22, 2003
    Assignee: Merck Patent GmbH
    Inventors: Holger Krummradt, Klaus Beschmann, Frank-Hardi Wartenberg, Horst Diekmann
  • Antidiabetic 4-hydroxy-2-furoic acids
    Patent number: 6596760
    Abstract: Substituted 4-hydroxy-2-furoic acids are obtained by the fermentation of an asterriquinone, which is a natural product having a 2,5-dioxy-3,6-bis(indolyl)quinone structure. The compounds modulate insulin receptor tyrosine kinase activity and may be useful in the treatment of diabetes and other diseases or conditions characterized by impaired endogenous insulin production or an impaired response to endogenous insulin.
    Type: Grant
    Filed: October 18, 2002
    Date of Patent: July 22, 2003
    Assignee: Merck & Co. Inc.
    Inventors: Shieh-Shung Tom Chen, Bei B. Zhang, Xiaohua Li
  • Interference pigments
    Patent number: 6596070
    Abstract: The present invention relates to interference pigments on the basis of multiply coated, platelet-shaped substrates which comprise at least one layer sequence comprising (A) a coating having a refractive index n≧2.0, (B) a colorless coating having a refractive index n≦1.8, and (C) a nonabsorbing coating of high refractive index, and, if desired, (D) an external protective layer.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: July 22, 2003
    Assignee: Merck Patent Gesellschaft
    Inventors: Christoph Schmidt, Gerhard Pfaff, Christina Schank, Sabine Schoen
  • Benzopyrans and benzoxepines, pharmaceutical compositions comprising them and preparation process
    Patent number: 6596758
    Abstract: The present invention relates to benzopyrans and benzoxepines of formula (I), wherein X, A, R1, R2 and (R)p have the meanings as given in claim 1, which can be used in the treatment of dislipidaemias, atherosclerosis and diabetes, to pharmaceutical compositions comprising them and to processes allowing the preparation of these compounds.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: July 22, 2003
    Assignee: Merck Patent GmbH
    Inventors: Michel Brunet, Jean-Jaques Zeiller, Jean-Jaques Berthelon, Francis Contard, Guy Augert, Daniel Guerrier
  • Liquid-crystalline medium
    Patent number: 6596350
    Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds having positive dielectric anisotropy, characterized in that it comprises one or more compounds of the general formula I in which R, A1, Z1, Y and L are as defined herein.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: July 22, 2003
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Kazuaki Tarumi, Brigitte Schuler, Eike Poetsch, Volker Reiffenrath, Yukiomi Tanaka